Hormonal
Tirzepatide, a dual GLP-1 and GIP receptor agonist, produces significant weight loss (17.8% placebo-subtracted) in individuals with obesity without diabetes.
Tirzepatide is a once-weekly injection that significantly reduces body weight in people with obesity, even without diabetes. It works by mimicking two gut hormones (GLP-1 and GIP) to reduce appetite and improve metabolism. While effective, it can cause temporary gastrointestinal issues like nausea, which usually subside as your body adjusts.
Tirzepatide, a dual agonist for the glucose‑dependent insulinotropic polypeptide (GIP) and GLP‑1 receptors, has been observed to be associated with a significant placebo‑subtracted weight reduction of 17.8% in a 72‑week randomized controlled trial.
Why this rating
Based on a phase III RCT (SURMOUNT-1) with large sample size and significant p-values.
Source
Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article
Wael R. Sidrak et al. · Indian Journal of Endocrinology and Metabolism · 2024
DOI 10.4103/ijem.ijem_442_23
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →